HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Inclusion Criteria: * Male or female patients ≥ 18 years of age; * Patients with histological confirmed advanced melanoma; * BRAF V600E/ V600K mutation positive； * At least 1 site of radiographically measurable disease by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) of 0 to 1; * Life expectancy ≥ 3 months; * Can swallow the medicine, * UCG documenting LVEF ≥50% within seven days prior to initiation of dosing; * Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Platelet count ≥ 1.0 x lower limit of normal (LLN); Hemoglobin ≥ 90 g/L; Serum creatinine ≤ 1.5 x upper limit of normal (ULN); Serum aspartate transaminase (AST) or serum alanine transaminase (ALT)≤ 2.5x ULN, and ≤ 5.0 x ULN if liver metastases are present. Serum alkaline phosphatase （ALP）≤ 2.5x ULN and ≥ 2.5 x ULN if bone metastases are present; Total serum bilirubin ≤ 1.5 x ULN; Serum albumin ≥ 30 g/L; Coagulation function：INR ≤1.5×ULN；Activated partial thrombin time (APTT) ≤1.5×ULN; Creatine kinase (CK) ≤1× ULN * 10\. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures. * 11\. Be willing and able to complete all the study procedures and follow-up examinations. Exclusion Criteria: * Patients who have been previously treated with a BRAF and/or MEK inhibitors. * Patients with act…